DEF 14A: Celcuity Inc. Announces Details for 2024 Annual Stockholders Meeting, Including Director Elections and Incentive Plan Amendments

Celcuity Inc. will hold its 2024 Annual Meeting of Stockholders on May 9, 2024, to vote on director elections, ratification of the accounting firm, executive compensation, and amendments to the stock incentive plan.

Summary

• Celcuity Inc. will hold its 2024 Annual Meeting of Stockholders on May 9, 2024, at its Minneapolis offices.
• Stockholders will vote on the election of seven director nominees.
• They will also vote to ratify the appointment of Boulay PLLP as the independent registered public accounting firm for the year ending December 31, 2024.
• An advisory vote will be held on named executive officer (NEO) compensation and the frequency of such votes.
• Stockholders will also vote on approving a 1,500,000 share increase to the Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan.
• An amendment to the Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan increasing by 250,000 the number of incentive award shares that may be granted in any calendar year to any one eligible recipient will also be voted on.
• The record date for determining stockholders eligible to vote is March 12, 2024.
• The Board recommends voting FOR all director nominees, the ratification of Boulay PLLP, the approval of NEO compensation, a one-year frequency for NEO compensation votes, and the approval of both stock incentive plan amendments.
• As of March 12, 2024, there were 27,773,777 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive sentiment due to the company's efforts to align executive compensation with performance and maintain good corporate governance.

Positives

• The Board is recommending votes in favor of all proposals, indicating confidence in the company's direction.
• The proposed amendments to the stock incentive plan aim to attract and retain key employees, which is crucial for the company's growth and development.
• The company is committed to good corporate governance, as evidenced by the various committees and policies in place.

Risks

• If the appointment of Boulay is not ratified, the Audit Committee may reconsider its retention, potentially leading to additional costs and disruption.
• A significant vote against the named executive officer compensation could necessitate changes to the compensation program.
• Failure to meet the Nasdaq board diversity rules by the specified deadlines could result in non-compliance disclosures.

Future Outlook

The company anticipates the need to maintain competitive compensation levels for existing employees and to add new employees as it continues to execute its clinical development and commercialization plans.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, particularly in the biopharmaceutical industry, including seeking stockholder approval for executive compensation and equity incentive plans.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity awards, is generally consistent with industry practices for companies of similar size and stage in the biopharmaceutical sector.
• The proposed increases to the stock incentive plan are aimed at aligning executive compensation with that of similarly situated companies, suggesting a competitive landscape for talent acquisition and retention.
• The company's approach to risk oversight and corporate governance aligns with best practices recommended by regulatory bodies and institutional investors.

Related Party Transactions

• Brian F. Sullivan, the Chairman of the Board of Directors and our Chief Executive Officer, participated in the private placement and purchased 260,869 shares of common stock for an aggregate purchase price of $1,499,996.75 and was issued warrants to purchase 104,340 shares of common stock, on the same terms and conditions as the other Investors under the Securities Purchase Agreement
• Richard Nigon, one of our directors, holds 5,061 Investor Warrants and 17,807 Agent Warrants.
• Mr. Nigons son-in-law and two of Mr. Nigons adult children hold Investor Warrants to purchase an aggregate of 6,553, 79 and 553 shares of common stock, respectively.

Stakeholder Impact

• Approval of the stock incentive plan amendments could positively impact employees by providing them with equity-based compensation.
• The outcome of the votes on executive compensation and the appointment of the auditor will be of interest to shareholders.
• The company's commitment to good corporate governance aims to protect the interests of all stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will proceed with the Annual Meeting on May 9, 2024.
• The Board and Compensation Committee will consider the results of the advisory votes on executive compensation when making future decisions.

Key Dates

Keywords

stockholders meeting, proxy statement, director election, executive compensation, stock incentive plan, corporate governance, Boulay PLLP, independent auditor, Nasdaq, Celcuity